Occurrence and significance of tumor-Associated neutrophils in patients with colorectal cancer

International Journal of Cancer

Volumn 139, Issue 2, 2016, Pages 446-456

  Galdiero, Maria Rosaria ^a,b   Bianchi, Paolo ^a   Grizzi, Fabio ^a   Di Caro, Giuseppe ^a   Basso, Gianluca ^a   Ponzetta, Andrea ^a   Bonavita, Eduardo ^a   Barbagallo, Marialuisa ^a   Tartari, Silvia ^a   Polentarutti, Nadia ^a   Malesci, Alberto ^a,c   Marone, Gianni ^b   Roncalli, Massimo ^a,d   Laghi, Luigi ^a   Garlanda, Cecilia ^a,d   Mantovani, Alberto ^a,d   Jaillon, Sébastien ^a,d  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d HUMANITAS UNIVERSITY   (Italy)

Author keywords

colorectal cancer; innate immunity; neutrophils; predictive markers; prognosis

Indexed keywords

CD66B ANTIGEN; CD68 ANTIGEN; FLUOROURACIL; LYMPHOCYTE ANTIGEN; MYELOPEROXIDASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; B RAF KINASE; BIOLOGICAL MARKER; KRAS PROTEIN, HUMAN; MICROSATELLITE DNA; PROTEIN P21;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CELL DENSITY; COLORECTAL CANCER; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL CHEMOTAXIS; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ASSOCIATED NEUTROPHIL; COLORECTAL TUMOR; DISEASE COURSE; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; NEUTROPHIL; PATHOLOGY; PROGNOSIS; SURVIVAL ANALYSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; NEOPLASM STAGING; NEUTROPHIL INFILTRATION; NEUTROPHILS; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); SURVIVAL ANALYSIS;

EID: 84961732849     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30076     Document Type: Article

References (55)

1. Jemal A, Bray F, Center MM, et al., Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Bindea G, Mlecnik B, Tosolini M, et al., Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013; 39: 782-95.
3. Anitei MG, Zeitoun G, Mlecnik B, et al., Prognostic and predictive values of the immunoscore in patients with rectal cancer. Clin Cancer Res 2014; 20: 1891-9.
4. Galon J, Costes A, Sanchez-Cabo F, et al., Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-4.
5. Hanahan D, Weinberg RA., Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
6. Mantovani A, Allavena P, Sica A, Balkwill F., Cancer-related inflammation. Nature 2008; 454: 436-44.
7. Terzic J, Grivennikov S, Karin E, Karin M., Inflammation and colon cancer. Gastroenterology 2010; 138: 2101-14e5.
8. Erreni M, Mantovani A, Allavena P., Tumor-Associated macrophages (TAM) and inflammation in colorectal cancer. Cancer Microenviron 2011; 4: 141-54.
9. Pages F, Berger A, Camus M, et al., Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353: 2654-66.
10. Laghi L, Bianchi P, Miranda E, et al., CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol 2009; 10: 877-84.
11. Mlecnik B, Tosolini M, Kirilovsky A, et al., Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011; 29: 610-8.
12. Di Caro G, Bergomas F, Grizzi F, et al., Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers. Clin Cancer Res 2014; 20: 2147-58.
13. Sica A, Mantovani A., Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 2012; 122: 787-95.
14. Galdiero MR, Bonavita E, Barajon I, Garlanda C, Mantovani A, Jaillon S., Tumor associated macrophages and neutrophils in cancer. Immunobiology 2013; 218: 1402-10.
15. Jaillon S, Galdiero MR, Del Prete D, et al., Neutrophils in innate and adaptive immunity. Semin Immunopathol 2013; 35: 377-94.
16. Kolaczkowska E, Kubes P., Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol 2013; 13: 159-75.
17. Mayadas TN, Cullere X, Lowell CA., The multifaceted functions of neutrophils. Annu Rev Pathol 2014; 9: 181-218.
18. Scapini P, Cassatella MA., Social networking of human neutrophils within the immune system. Blood 2014; 124: 710-9.
19. Dumitru CA, Lang S, Brandau S., Modulation of neutrophil granulocytes in the tumor microenvironment: mechanisms and consequences for tumor progression. Semin Cancer Biol 2013; 23: 141-8.
20. Tecchio C, Scapini P, Pizzolo G, Cassatella MA., On the cytokines produced by human neutrophils in tumors. Semin Cancer Biol 2013; 23: 159-70.
21. Matsushima H, Geng S, Lu R, et al., Neutrophil differentiation into a unique hybrid population exhibiting dual phenotype and functionality of neutrophils and dendritic cells. Blood 2013; 121: 1677-89.
22. Fridlender ZG, Sun J, Kim S, et al., Polarization of tumor-Associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 2009; 16: 183-94.
23. Tsuda Y, Takahashi H, Kobayashi M, et al., Three different neutrophil subsets exhibited in mice with different susceptibilities to infection by methicillin-resistant Staphylococcus aureus. Immunity 2004; 21: 215-26.
24. Finisguerra V, Di Conza G, Di Matteo M, et al., MET is required for the recruitment of anti-tumoural neutrophils. Nature 2015; 522: 349-53.
25. Noy R, Pollard JW., Tumor-Associated macrophages: from mechanisms to therapy. Immunity 2014; 41: 49-61.
26. Trellakis S, Farjah H, Bruderek K, et al., Peripheral blood neutrophil granulocytes from patients with head and neck squamous cell carcinoma functionally differ from their counterparts in healthy donors. Int J Immunopathol Pharmacol 2011; 24: 683-93.
27. Kuang DM, Zhao Q, Wu Y, et al., Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol 2011; 54: 948-55.
28. Jensen HK, Donskov F, Marcussen N, et al., Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol 2009; 27: 4709-17.
29. Wislez M, Rabbe N, Marchal J, et al., Hepatocyte growth factor production by neutrophils infiltrating bronchioloalveolar subtype pulmonary adenocarcinoma: role in tumor progression and death. Cancer Res 2003; 63: 1405-12.
30. Droeser RA, Hirt C, Eppenberger-Castori S, et al., High myeloperoxidase positive cell infiltration in colorectal cancer is an independent favorable prognostic factor. PLoS One 2013; 8: e64814.
31. Rao HL, Chen JW, Li M, et al., Increased intratumoral neutrophil in colorectal carcinomas correlates closely with malignant phenotype and predicts patients' adverse prognosis. PLoS One 2012; 7: e30806.
32. Roncucci L, Mora E, Mariani F, et al., Myeloperoxidase-positive cell infiltration in colorectal carcinogenesis as indicator of colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2008; 17: 2291-7.
33. Laghi L, Bianchi P, Delconte G, et al., MSH3 protein expression and nodal status in MLH1-deficient colorectal cancers. Clin Cancer Res 2012; 18: 3142-53.
34. Ghidini M, Personeni N, Bozzarelli S, et al., KRAS mutation in lung metastases from colorectal cancer: prognostic implications. Cancer Med 2015; 5: 256-264. CrossRef][10.1002/cam4.592]
35. Schmoll HJ, Van Cutsem E, Stein A, et al., ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol 2012; 23: 2479-516.
36. Sargent DJ, Marsoni S, Monges G, et al., Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010; 28: 3219-26.
37. Sinicrope FA, Shi Q, Smyrk TC, et al., Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology 2015; 148: 88-99.
38. Taieb J, Zaanan A, Le Malicot K, et al., Prognostic Effect of BRAF and KRAS mutations in patients with stage III colon cancer treated with leucovorin, fluorouracil, and oxaliplatin with or without cetuximab: A post hoc analysis of the PETACC-8 trial. JAMA Oncol 2016; 1-11. doi:10.1001/jamaoncol.2015.5225.
39. Sica A, Erreni M, Allavena P, et al., Macrophage polarization in pathology. Cell Mol Life Sci 2015; 72: 4111-26.
40. Grivennikov SI, Wang K, Mucida D, et al., Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 2012; 491: 254-8.
41. Grizzi F, Bianchi P, Malesci A, et al., Prognostic value of innate and adaptive immunity in colorectal cancer. World J Gastroenterol 2013; 19: 174-84.
42. Klebanoff SJ., Myeloperoxidase: friend and foe. J Leukoc Biol 2005; 77: 598-625.
43. Nakamori S, Kameyama M, Imaoka S, et al., Increased expression of sialyl Lewisx antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study. Cancer Res 1993; 53: 3632-7.
44. Mantovani A, Allavena P., The interaction of anticancer therapies with tumor-Associated macrophages. J Exp Med 2015; 212: 435-45.
45. Zitvogel L, Galluzzi L, Smyth MJ, et al., Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013; 39: 74-88.
46. De Palma M, Lewis CE., Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 2013; 23: 277-86.
47. Di Caro G, Cortese N, Castino GF, et al., Dual prognostic significance of tumour-Associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy. Gut 2015. doi:10.1136/gutjnl-2015-309193.
48. Kroemer G, Galluzzi L, Kepp O, et al., Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31: 51-72.
49. Ghiringhelli F, Bruchard M, Apetoh L., Immune effects of 5-fluorouracil: ambivalence matters. Oncoimmunology 2013; 2: e23139.
50. Vincent J, Mignot G, Chalmin F, et al., 5-Fluorouracil selectively kills tumor-Associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 2010; 70: 3052-61.
51. Bruchard M, Mignot G, Derangere V, et al., Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med 2013; 19: 57-64.
52. Ghiringhelli F, Apetoh L, Tesniere A, et al., Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15: 1170-8.
53. Lukac J, Kusic Z, Kovacevic D, et al., Neutrophil and monocyte phagocytic functions in patients with colorectal adenocarcinoma during fluorouracil therapy. Anticancer Res 1995; 15: 2805-9.
54. Sakai H, Sagara A, Matsumoto K, et al., Neutrophil recruitment is critical for 5-fluorouracil-induced diarrhea and the decrease in aquaporins in the colon. Pharmacol Res 2014; 87: 71-9.
55. Granot Z, Henke E, Comen EA, et al., Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell 2011; 20: 300-14.